Télésurveillance médicale en oncologie en France : état des lieux entre 2022 et 2025
Bulletin du Cancer · 2026-11 · 113 (11) · 1244-1252
DOI: 10.1016/j.bulcan.2026.08.005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bulletin du Cancer, 2026-11. Verfasst von Emma Di Méglio und 6 weiteren Autor:innen. Beteiligte Einrichtung: Université de Montpellier, Montpellier, France; Service d'oncologie médicale, CHU Carémeau - Institut de cancérologie du Gard, Nîmes, France. Electro…. Hauptthemen laut MEDLINE: Neoplasms, Medical Oncology, Telemedicine. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
BACKGROUND: In oncology, telemonitoring symptoms of patients has shown significant benefits in terms of overall survival and quality of life in several clinical trials in oncology. Telemonitoring has been reimbursed in France since 2023. Our study aims to establish a French overview of telemonitoring in oncology between 2022 and 2025. METHODS: In 2022, 113 pharmacists in cancer departments authorized to produce chemotherapy in France, and then 78 in 2025, completed an electronic form about their use of telemonitoring in their departments. RESULTS: Among the responding centres, 12.61% used telemonitoring in oncology in 2022 versus 35.90% in 2025. These centers described similar obstacles to the implementation of these platforms in both studies, such as lack of interoperability, limitation on patient use, lack of human resources and clinician engagement. CONCLUSION: Since their reimbursement in 2023, telemonitoring platforms in French cancer departments has been developed, but difficulties persist in routine practice, due to a lack of resources for professionals. This requires better training for professionals and optimization of the platform by developers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Université de Montpellier, Montpellier, France; Service d'oncologie médicale, CHU Carémeau - Institut de cancérologie du Gard, Nîmes, France. Electronic address: emma.di-meglio@hotmail.com.
- Unité de pharmacie clinique oncologique, CHU de Montpellier, Montpellier, France.
- Service de pharmacie, CHU Carémeau - Institut de cancérologie du Gard, Nîmes, France.
- Université de Montpellier, Montpellier, France; Service d'oncologie médicale, CHU Carémeau - Institut de cancérologie du Gard, Nîmes, France; Institut de recherche en cancérologie de Montpellier, Inserm U1194, Montpelli…
Zitieren
APA
Di Méglio, E., Hocine, M., Coget, E., Brouard, P., Cousin, C., Carbasse, C., & Fiteni, F. (2026). Télésurveillance médicale en oncologie en France : état des lieux entre 2022 et 2025. Bulletin du Cancer, 113(11), 1244-1252. https://doi.org/10.1016/j.bulcan.2026.08.005
Vancouver
Di Méglio E, Hocine M, Coget E, Brouard P, Cousin C, Carbasse C, et al. Télésurveillance médicale en oncologie en France : état des lieux entre 2022 et 2025. Bulletin du Cancer. 2026;113(11):1244-1252. doi:10.1016/j.bulcan.2026.08.005
BibTeX
@article{DiMglio2026,
author = {Di Méglio, Emma and Hocine, Mélina and Coget, Emmanuel and Brouard, Pascale and Cousin, Christelle and Carbasse, Clément and Fiteni, Frédéric},
title = {Télésurveillance médicale en oncologie en France : état des lieux entre 2022 et 2025},
journal = {Bulletin du Cancer},
year = {2026},
volume = {113},
number = {11},
pages = {1244--1252},
doi = {10.1016/j.bulcan.2026.08.005}
}
EUVIMED